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The ammo acid sequence of a rat opioid receptor, designated as ROR-D, has been deduced by cloning and sequencing the cDNA. The ROR-D 
expressed from the cDNA exhibits high affinities for ligands selective for the opiotd receptor K-subtype and low affinities for ligands selective for 
the 6- and p-subtypes RNA blot hybridization analysis indicated that ROR-D mRNA is distributed m cerebrum and bramstem but not m 
cerebellum. 
Opioid receptor: cDNA cloning: cDNA expression: RNA blot hybridization analysis. Rat brain 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Opioid analgesics produce their pharmacological ac- 
tions by interacting specifically with opioid receptors in 
the nervous system [I]. The opioid receptors mediate 
cellular inhibitory effects, including inhibition of 
adenylate cyclase, activation of potassium channels and 
inhibition of calcium channels. through the action of 
guanine nucleotide-binding regulatory proteins (G-pro- 
teins) [2.3]. Pharmacological studies have defined at 
least three distinguishable subtypes @, IC and 6) of the 
opioid receptors on the basis of their difference in affin- 
ities for opioid ligands [1,2]. 
Recently, the cDNA cloning of the 6- and the ,LI- 
subtype opioid receptor has been reported and phar- 
macological properties of the receptors expressed from 
the cDNAs have been studied [4-61. In this report, we 
have cloned cDNA encoding an opioid receptor sub- 
type, designated as ROR-D, from rat cerebrum cDNA 
libraries, and studied its ligand-binding properties by 
expression of the cDNA in COS cells. The results 
showed that the pharmacological properties of the ex- 
pressed ROR-D correspond most likely to those of the 
rc-opioid receptor subtype. 
*Corresponding author. Fax, (81) (75) 811 8186. 
Abbrevrationst G-proteins, guamne nucleotide-binding regulatory pro- 
teins; EKC, ethylketocyclazocine; DADLE. [D-Ah’.D-LeU5]- 
enkephalin; DPDPE, [o-penicillamme’,D-pemcillamine5]enkephahn; 
DAGO, [o-AlaZ.MePhe”,Gly-o15]enkephahn. 
2.1. Clonrng of cDNA 
Rat cerebrum cDNA libraries [6] were screened with the -1.4- 
kilobase pairs (kb) Hind111 fragment derived from pROR15 [6], or an 
equimolar mixture of the 0.54-kb and 0.52-kb .%a1 fragments derived 
from pROR1 [6], as probes. cDNA inserts from clones positive to both 
probes were subcloned mto pBluescript SK(-) and further analyzed. 
cDNA inserts of 3 clones, including pROR201 and pROR302, share 
a common restriction endonuclease map (PstI. Hl?zdIII. XhoI. SpeI, 
XbaI and EcoRI). which differs from those of the ROR-A and ROR-B 
cDNAs [6], and are mdicated to be derived from identical mRNAs. 
designated as ROR-D. The cDNA clones, pROR201 and pROR302, 
carrymg the entire protein-coding sequence, were used for sequence 
analysis [7.8]. 
2.2. E.upre.won of cDNA and Irgand-hindmg assay 
The 0.38-kb PstIIEcoRI and 0.78-kb EcoRIISpeI fragments from 
pROR201 were ligated with the PstI-SpeI fragment from pBluescrtpt 
SK(-) to yield pRORSZOl-1. pRORS301-1 was digested with XbaI, 
blunt-ended with T, DNA polymerase, and then ligated with the 
synthetic Hind111 linker to yield pRORS201-2. pRORS201-2 was par- 
tially digested with HindIII. and the resulting 1.2-kb fragment carrymg 
the entire protein-coding sequence of ROR-D was cloned mto the 
Hind111 site of an expression vector, pKCRH2 [9], in the same orien- 
tation with respect to SV40 early promoter to generate pRORS201-4. 
COS-7 cells were transfected [lo] with pRORSZOl-4 and harvested 
after 223 days. Crude membranes were prepared and assayed for 
[‘HIEKC bindmg as in [6]. except that reactions were performed in 0.2 
ml using 20 /g of membrane preparations. 
2 3. RNA blot hyhrrdlzation analysrs 
Poly(A)’ RNAs prepared from adult Wistar rats were analyzed as 
in [6]. The hybridization probe used was the -2.3-kb cDNA insert of 
pROR201. The probe was labelled with [a-Z’P]dCTP by the random 
primer method [l 11. Autoradiography was performed at -80°C for 3 
days with an intensifying screen. An RNA ladder (Bethesda Research 
Laboratories) was used as size markers. 
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3. RESULTS AND DISCUSSION 
Rat cerebrum cDNA libraries were screened by hy- 
bridization with probes derived from the rat 6- and 
p-opioid receptor cDNAs, and a novel class of cDNA 
clones (ROR-D) was isolated (see section 2.1). Nucleo- 
tide sequence analysis of the cDNAs reveals an open 
reading frame of 1,140 nucleotides encoding a sequence 
of 380 amino acids. Fig. 1 shows the deduced amino 
acid sequence of the ROR-D protein aligned with those 
of ROR-A (the 6-opioid receptor subtype) and ROR-B 
(the p-subtype). Amino acid sequence comparison re- 
veals 59% and 58% identities between ROR-D/ROR-A 
and ROR-D/ROR-B pairs, respectively. The ROR-D 
protein shares characteristic structural features with G- 
protein-coupled receptors [ 121. Seven transmembrane 
segments are predicted in the ROR-D molecule, and 
two consensus N-glycosylation sites [13] occur in the 
amino-terminal region preceding the predicted trans- 
membrane segment, TM-I. In the ROR-D, ROR-A and 
ROR-B molecules, the carboxy-terminal region just fol- 
lowing TM-VII contains two conserved cysteine resi- 
dues that may be modified by palmitoylation [13]. The 
cytoplasmic portion between TM-V and TM-VI. which 
has been suggested to determine the selectivity of G- 
protein coupling [ 14,151, is conserved well among these 
molecules, thus they may couple with similar G-pro- 
teins. 
An expression plasmid (pRORS201-4) was con- 
structed in which the entire protein-coding sequence of 
ROR-D is positioned downstream of the SV40 pro- 
moter. as in section 2.2. Fig. 2 shows that membrane 
preparations from COS cells transfected with 
pRORS201-4 were capable of binding [“HIEKC, a high- 
affinity ligand for opioid receptor subtypes, whereas 
negligible binding was found for non-transfected COS 
cells. The dissociation constant (M for EKC was esti- 
mated by Scatchard analysis to be 0.48 nM (mean of 
two experiments). Ligand-binding properties of the ex- 
pressed ROR-D were further examined in comparison 
with those of ROR-A and ROR-B. The apparent K,, 
values for representative opioid ligands are listed in 
Table I. ROR-D showed lower binding affinities for 
peptide agonists selective for the 6- and p-opioid recep- 
tor subtypes (DADLE with a high affinity for the 6- and 
p-subtypes. DPDPE selective for the &subtype, and 
DAGO selective for the p-subtype) than ROR-A and 
ROR-B. Morphine and naloxone had moderate affini- 
ties for ROR-D among these receptor subtypes. On the 
other hand, ROR-D exhibited much higher affinities for 
K-subtype-selective ligands (U50488, U69593 and EKC) 
than ROR-A and ROR-B. These results indicated that 
ROR-D corresponds most closely to the pharmacologi- 
cally defined Ic-opioid receptor subtype. Recent studies 
have suggested that the K-opioid receptor subtype can 
be further classified into the Ic,-type (with a high affinity 
for U69593) and the rc,-type (with a low affinity) [ 16,171. 
ROR-D exhibited a K,, = 30 nM for U69593 and may, 
therefore, belong to the Ic,-type. 
The affinity profile of dynorphin( l-13) for cloned 
opioid receptor species was not consistent with previous 
observations using brain microsomal preparations. 
Many experiments have shown that dynorphin( l-1 3) 
exhibits the highest affinity for the K-subtype among 
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Ftg. 1. Deduced ammo acid sequence of ROR-D (bottom) and its ahgnment with those of the &optotd receptor. ROR-A (top). and the ,woptotd 
receptor, ROR-B (mtddle). Sequence data for ROR-A and ROR-B have been taken from [6]. The one-letter amino actd notatton 1s used. Gaps (-) 
have been mserted to achteve maxrmum homology. Ammo actd residues arc numbered from the imttatmg methtomne and numbers of the restdues 
at the right-hand end ofthe indiwdual lmes are gwen. The predicted transmembrane segments (TM-IPVII) are mdtcated: the termmi ofeach segment 
are tentatively asstgned. The nucleotlde sequence of ROR-D ~111 appear in the DDBJ. EMBL. GenBank Nucleottde Sequence Databases under 
accessron number D16534. 
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Fig. 2. Bindmg of [‘HIEKC to the ROR-D spectes expressed m COS 
cells. Membrane preparattons from pRORS201-4-transfected COS 
cells (0) and non-transfected COS cells (m) were analyzed. The mset 
shows Scatchard plots of thedata. The non-specific bmding (measured 
in the presence of excess amount of unlabelled naloxone) was less than 
16% of the total radioacttvity bound. 
opioid receptor subtypes in the brain [18,19]. In con- 
trast, dynorphin(l-13) showed the lowest affinity for 
ROR-D in our results (Table I). This discrepancy might 
suggest that other K-subtype receptors with higher affin- 
ities for dynorphin than that of ROR-D exist in the 
brain, and/or that brain-specific modifications of the 
ROR-D molecule are required for a high affinity for 
dynorphin. 
Table I 
Ligand-bmding properties of defined opiotd receptor species ex- 
pressed from cDNAs 
Ltgands Apparent K,, (nM) 
ROR-D ROR-A ROR-B 
DADLE >10.000 5.0 1.9 
DPDPE >10,000 28 1,900 
DSLET ND 12 142 
DAGO 3,000 2.240 4.0 
Morphine 300 1,260 5.3 
Naloxone 15 67 1.8 
EKC 0.48 3.3* 0.93* 
U50488 12 >10,000 710 
U69593 30 3.400* 3,100* 
Dynorphm(l-13) 210 53’ 40’ 
The K,, values of ROR-D for EKC were obtained by Scatchard anal- 
ysis and those for the other ligands were obtained by measurmg dis- 
placement of [‘HIEKC binding; means of at least two experiments are 
given. The Kd values of ROR-A and ROR-B have been taken from 
[6] and unpublished experiments using [‘H]EKC (marked by asterisks) 
or [‘HIDADLE (marked by plus signs). ND, not determmed. 
95- 
75- 
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Ftg. 3. Autoradiograms of blot hybridization analysis of poly(A)’ 
RNA from rat ttssues with the probe from ROR-D cDNA Samples 
of poly(A)+ RNA (3Opg each) prepared from kidney (lane 1). cerebel- 
lum (lane 2). brainstem (lane 3) and cerebrum (lane 4) were analyzed 
as m section 2.3. The size markers are Indicated in kb. 
Poly(A)’ RNA preparations from rat tissues were 
subjected to blot hybridization analysis (Fig. 3). Cere- 
brum and brainstem contained an RNA species of -5.2 
kb hybridizable with the probe derived from the ROR- 
D cDNA. No hybridizable RNA species was detected 
in cerebellum and kidney. This result is consistent with 
previous observations by autoradiographic experiments 
using radioligands [20]. which showed that the Fc-opioid 
receptor subtype is distributed throughout the rat cen- 
tral nervous system except cerebellum. We have previ- 
ously shown that cerebrum and brainstem also contain 
ROR-A and ROR-B mRNAs. Thus, the opioid recep- 
tor heterogeneity in the nervous system with respect to 
ligand binding is attributable to various combinations 
of distinct opioid receptor gene products, including 
ROR-D, ROR-A and ROR-B. 
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